Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;14(8):1987-1994.
doi: 10.1080/21645515.2018.1454571. Epub 2018 May 10.

Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV)

Zhuofan Li  1 , Wenting Ding  1 , Qi Guo  1 , Ze Liu  1 , Zhe Zhu  1 , Shaohui Song  1 , Weidong Li  2 , Guoyang Liao  1
Affiliations

Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV)

Zhuofan Li et al. Hum Vaccin Immunother. 2018.

Abstract

Sabin-based inactivated poliovirus vaccine(sIPV) is gradually replacing live-attenuated oral polio vaccine(OPV). Sabin-inactivated poliovirus vaccine(sIPV) has played a vital role in reducing economic burden of poliomyelitis and maintaining appropriate antibody levels in the population. However, due to its high cost and limited manufacturing capacity, sIPV cannot reach its full potential for global poliovirus eradication in developing countries. Therefore, to address this situation, we designed this study to evaluate the dose-sparing effects of AS03, CpG oligodeoxynucleotides (CpG-ODN) and polyinosinic:polycytidylic acid (PolyI:C) admixed with sIPV in rats. Our results showed that a combination of 1/4-dose sIPV adjuvanted with AS03 or AS03 with BW006 provides a seroconversion rate similar to that of full-dose sIPV without adjuvant and that, this rate is 5-fold higher than that of 1/4-dose sIPV without adjuvant after the first immunization. The combination of AS03 or AS03 with BW006 as an adjuvant effectively reduced sIPV dose by at least 4-fold and induced both humoral and cellular immune responses. Therefore, our study revealed that the combination of AS03 or AS03 with BW006 is a promising adjuvant for sIPV development.

Keywords: AS03; CpG ODN; adjuvant; polyi:C; sabin IPV.

PubMed Disclaimer

Figures

Figure 1a.
Figure 1a.
Poliovirus antigen specific IgG after the first immunization.
Figure 1b.
Figure 1b.
Poliovirus antigen specific IgG after the second immunization.
Figure 2.
Figure 2.
The weight of rats 3 days after the first immunization and every subsequent 7 days.
Figure 3a.
Figure 3a.
IgG1 and IgG2a for type II poliovirus after the first immunization.
Figure 3b.
Figure 3b.
IgG1 and IgG2a for type II poliovirus after the second immunization.
See this image and copyright information in PMC

References

    1. Home C. Laboratory surveillance for wild and vaccine-derived polioviruses--worldwide, January 2007-June 2008. Mmwr Morbidity & Mortality Weekly Report. 2008;57:967. - PubMed
    1. Roberts L. A one-two punch against polio. Petroleum Rock Mechanics. 2014;345:63–76.
    1. Bahl S, Bhatnagar P, Sutter RW, Roesel S, Zaffran M. Global Polio Eradication - Way Ahead. The Indian Journal of Pediatrics. 2018;85:124–131. doi: 10.1007/s12098-017-2586-8. PMID:29302865.25316847 - DOI - PMC - PubMed
    1. Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-Derived Polioviruses. Journal of Infectious Diseases. 2014;210(Suppl 1):S283. doi: 10.1093/infdis/jiu295. PMID:25316847. - DOI - PubMed
    1. Platt LR, Estívariz CF, Sutter RW. Vaccine-Associated Paralytic Poliomyelitis: A Review of the Epidemiology and Estimation of the Global Burden. Journal of Infectious Diseases. 2014;210(Suppl 1):S380. doi: 10.1093/infdis/jiu184. PMID:25316859. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources